Madrigal Pharmaceuticals

US Pricing Pressure And European Payers Will Erode Margins

AnalystLowTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

27 Aug 25

Updated

27 Aug 25

AnalystLowTarget's Fair Value

US$311.98

36.2% overvalued

27 Aug

US$425.06

70.9%

4.4%

70.9%

4.4%

Author's Valuation

US$312.0

36.2% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$312.0

36.2% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

35.88%

Biotech revenue growth rate

12.30%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$398.69m

Earnings '28

21.91x

PE Ratio '28

US$8.74b

Market Cap '28

US$8.74b

Market Cap '28

23.79m

No. shares '28

US$367.21

Share Price '28

US$367.21 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$301.64

Fair Value '25